Suche
Mein Konto
Resveratrol prevents bone density loss in patients with type 2 diabetes
Resveratrol prevents bone density loss in patients with type 2 diabetes By Prof. Gene Bruno, MS, MHS, RH(AHG), Huntington University of Health Sciences Patients with type 2 diabetes (T2DM) are at increased risk of fractures, and researchers are continually looking for strategies to prevent bone loss and reduce the risk of fractures reduce. One potentially promising strategy is the use of resveratrol. Preclinical Research on Resveratrol for Bone Health Animal studies have shown that resveratrol prevents bone loss, reduces mineral density due to immobilization, older age, and ovariectomy1-4, and promotes bone healing and repair after surgery or trauma.5-6 It promotes osteoblastogenesis, antagonizing osteoclasts in vitro,7-9 and enhanced...
Resveratrol prevents bone density loss in patients with type 2 diabetes
Resveratrol prevents bone density loss in patients with type 2 diabetes
By Prof. Gene Bruno, MS, MHS, RH(AHG), Huntington University of Health Sciences
Patients with type 2 diabetes (T2DM) are at increased risk of fractures, and researchers are continually looking for strategies to prevent bone loss and reduce fracture risk. One potentially promising strategy is the use of resveratrol.
Preclinical research on resveratrol for bone healthAnimal studies have shown that resveratrol prevents bone loss, reduces mineral density due to immobilization, older age, and ovariectomy,1-4, and promotes bone healing and repair after surgery or trauma.5-6 It promotes osteoblastogenesis, antagonizing osteoclastsin vitro,7-9 and increased vitamin D receptor activity.10
A Human Clinical Trial of Resveratrol for Bone HealthGiven these positive preclinical results, a double-blind, randomized, placebo-controlled study11 was conducted to investigate the effects of resveratrol on bone mineral density (BMD) and biomarkers of calcium metabolism in T2DM patients. A total of 192 T2DM outpatients were randomized to receive resveratrol 500 mg/day (Resv500 arm), resveratrol 40 mg/day (Resv40 arm), or placebo for six months. BMD, bone mineral content (BMC), serum calcium, phosphorus, alkaline phosphatase and 25-hydroxy vitamin D were measured at baseline and six months. The results were that at follow-up, calcium concentrations increased in all patients, while within-group variations in alkaline phosphatase were higher in both resveratrol arms and 25-hydroxy-vitamin D increased only in the Resv500 arm, with no differences between groups. Whole-body BMD significantly decreased in the placebo group, while whole-body BMC decreased in both the placebo and Resv40 arms. There were no significant changes in BMD and BMC values in the Resv500 arm. The adjusted mean differences in change from baseline were significantly different in the Resv500 arm compared to placebo for whole-body BMD (0.01 vs -0.03 g/cm2, p = 0.001), whole-body BMC (4.04 vs -58.8 g, p < 0.001). ), whole body T-score (0.15 vs – 0.26) and serum phosphorus (0.07 vs – 0.01 µmol/l, p = 0.002). In subgroup analyses, BMD values of Resv500-treated patients increased to higher values in patients with lower calcium and 25-hydroxy vitamin D levels and in alcohol drinkers. In conclusion, supplementation with 500 mg resveratrol prevented bone density loss in patients with T2DM, particularly in those with adverse baseline conditions.
References:
Professor Gene Bruno, MS, MHS, provost for Huntington College of Health Sciences, is a nutritionist, herbalist, author and educator. For more than 37 years, he has educated and trained natural products retailers and healthcare professionals, researched and formulated natural products for dozens of dietary supplement companies, and authored articles on nutrition, herbal medicine, nutraceuticals, and integrative health topics for trade and consumer magazines and peer-reviewed publications. He can be reached at gbruno@hchs.edu.
- Prof. Gene Bruno Blog
Read original article in English.